How much did Atai stock gain?

Atai shares surged up to 53% in premarket trading.

Is there any official confirmation of the acquisition deal?

No, the reports are still unconfirmed, and neither company has issued an official statement.

GH Research Jumps 12% on Eli Lilly-Atai Acquisition Talks

GH Research (GHRS) shares climbed about 12% in premarket trading on Thursday following reports that Eli Lilly (LLY) is in discussions to acquire psychedelic drug developer Atai Life Sciences (ATAI), sparking renewed investor interest across the sector.

July 16, 2026

2 min read

Source: InvestorsHub

Key Numbers

ghrs premarket gain

~12%

atai premarket gain

53%

Potential Reasons

The direct catalyst is the report that Eli Lilly is in talks to acquire Atai Life Sciences, a company focused on developing psychedelic drugs for mental health conditions. This development has ignited investor enthusiasm for the entire psychedelic drug sector, including GH Research.

Context

Atai shares surged as much as 53% before the opening bell, reflecting expectations that big pharma may pursue acquisitions in the psychedelic space. GH Research, which also operates in this field, benefited from the positive sentiment.

Similar Moves in the Sector

Other psychedelic drug developers also saw modest gains, but GH Research was the most notable after Atai. Such moves often occur when a major acquisition rumor surfaces in an emerging sector, as investors bet on similar deals.

Frequently Asked Questions

The stock rose about 12% after reports of Eli Lilly's acquisition talks with Atai Life Sciences, boosting sentiment in the psychedelic drug sector.

Found this useful? Share it

This article was rewritten in Wrqti's editorial style based on information from the original source above. Content is informational only — not investment advice.